Recommended Information
In vitro–differentiated Th1/Th17/Treg cells
Antibody-Dependent Cell-Mediated Cytotoxicity Assay (ADCC)
Antibody-dependent cellular phagocytosis
Complement-dependent cytotoxicity (CDC)
Cytokine Release Syndrome Risk Assessment (CRS)
Flow Cytometry-Based Cell Characterization Experiments (FACS)
In vitro–differentiated Th1/Th17/Treg cells
CD4+ helper T cells (Th cells) serve as mediators of cellular immunity and play a critical role in activating other immune cells, such as B cells and cytotoxic T cells, as well as in regulating immune responses.
CD4+ helper T lymphocytes (Th cells) serve as mediators of cellular immunity and play a pivotal role in activating other immune cells, such as B cells and cytotoxic T cells, as well as in regulating immune responses. Undifferentiated CD4+ Th cells are referred to as naïve CD4+ T cells or Th0 precursor cells; upon antigen recognition, these naïve CD4+ T cells undergo clonal expansion and, under the influence of various cytokines, transcription factors, co-stimulatory signals, and adhesion molecules, differentiate into distinct effector cell subsets—namely, the CD4+ Th cell subsets. These subsets include Th1, Th2, Th17, and regulatory T cells (Tregs). Each subset is activated by a specific set of cytokines and transcription factors and exerts unique effector functions by secreting distinct cytokines. Moreover, these cytokines mutually regulate one another, maintaining a delicate and complex immune balance that is essential for optimal immune homeostasis and for the effective execution of cellular immune responses.
Th17 cells represent the third major subset of effector CD4+ T helper cells, following the discovery of Th1 and Th2 cells, and are named for their high-level secretion of IL-17. Th17 cells primarily produce cytokines such as IL-17A, IL-17F, IL-21, and IL-22, and express the transcription factors retinoic acid–related orphan receptor γt (RORγt) and RORα. They play a critical role in host defense against extracellular pathogens, particularly at mucosal and epithelial barriers; however, dysregulation of Th17 cells is associated with the pathogenesis of numerous autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other conditions.
Th17 cells have now become a research hotspot in the field of immunology, with an increasing number of studies exploring these cells and their cytokine products as therapeutic targets for various autoimmune diseases. Consequently, the efficient in vitro generation of large numbers of homogeneous and stable Th17 cells has emerged as a prerequisite for advancing Th17 cell research. However, variations in in vitro differentiation and expansion protocols often result in significant heterogeneity among the derived Th17 cells, characterized by insufficient cell numbers, poor homogeneity, and/or instability, making them prone to transdifferentiation or dedifferentiation.
Therefore, there is an urgent need to develop a rapid, efficient, and robust method for the in vitro differentiation and expansion of Th17 cells, yielding sufficient numbers with high homogeneity and stability. Such a method would be well suited for investigating the molecular mechanisms underlying immune regulation and immune homeostasis, as well as for evaluating the biological activities of therapeutic agents targeting diseases or conditions associated with aberrant Th17 cell activation.
Service Advantages:
Quality System
1. Strictly adhere to the protocols for subject screening, sample collection, and sample management.
2. Complete ethical approval documentation that complies with the review requirements of the ethics committee and other regulatory compliance obligations, including corporate audits. Supports on-site client inspections.
3. A professional cold-chain logistics collaboration system ensures compliant and efficient delivery of samples throughout the entire process.
R&D System
1. Focused on cell therapy, gene therapy, and the development of large-molecule drugs.
2. Continuously optimize standardized preparation processes and lead industry service standards.
3. Innovate service models and expand the boundaries of research applications
Professional Team
1. A seasoned R&D team and a mature, standardized cell preparation process and manufacturing system.
2. Standardized donor registry and management system covering both Chinese and international populations
Core Resources
1. World-class production and service equipment, state-of-the-art laboratory facilities, and a nearly 1,000-square-meter R&D center.
2. Establish multiple clinical collaboration centers, with the East China region as the leading hub, covering tertiary hospitals nationwide and high-quality GCP management centers.
3. Our in-house specialized project team can provide clients with services such as regulatory interpretation, policy analysis, domestic-investor qualification determination, and approval for foreign-invested cooperation, offering one-stop compliance support.
Keyword